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Abstract
Introduction: Chryseobacterium indologenes is an uncommon human pathogen. Most infections have been
detected in hospitalized patients with severe underlying diseases who had indwelling devices implanted. Infection
caused by C. indologenes in a newborn has not been previously reported.
Case presentation: We present a case of ventilator-associated pneumonia caused by C. indologenes in a full-term
Caucasian newborn baby boy with congenital heart disease who was successfully treated with piperacillin-tazobactam.
Conclusion: C. indologenes should be considered as a potential pathogen in newborns in the presence of invasive
equipment or treatment with long-term broad-spectrum antibiotics. Appropriate choice of effective antimicrobial
agents for treatment is difficult because of the unpredictability and breadth of antimicrobial resistance of these
organisms, which often involves resistance to many of the antibiotics chosen empirically for serious Gram-negative
infections.
Introduction
Chryseobacterium spp. are Gram-negative bacilli widely
distributed in soil and water. In hospital environments,
they have been recovered from water systems and
humid surfaces. Infections caused by Chryseobacterium
indologenes are rare, but have been reported as a cause
of serious infections in adult immunosuppressed
patients. To the best of our knowledge, infection caused
by C. indologenes in a newborn has not been previously
reported.
Case presentation
Our patient, a full-term Caucasian newborn baby boy
with congenital heart disease (double-outlet right ventri-
cle, mitral atresia and hypoplastic aortic arch) remained
intubated and under mechanical ventilation from the
seventh day of life due to hemodynamic deterioration.
Then, 20 days later, he deteriorated clinically with wor-
sening fever, intense leukocytosis, increase of acute-phase
reactants and pulmonary infiltrate on chest radiograph.
Empiric antibiotic therapy with meropenem and vanco-
mycin was given. Bacteriological blood, cerebrospinal
fluid and urine culture test results were negative.
C. indologenes was isolated from a tracheobronchial
secretion sample obtained by endotracheal aspiration.
Treatment was discontinued at 10 days on clinical
improvement. Then, five days later, he again developed
fever and pulmonary infiltrate on chest radiograph.
C. indologenes was again isolated from respiratory sam-
ples obtained by bronchoalveolar lavage (BAL). No other
microorganisms were isolated from the BAL sample. The
bacteria were susceptible in vitro to fluoroquinolones,
cefepime, piperacillin-tazobactam and co-trimoxazole
with intermediate susceptibility to third-generation
cephalosporins; it was resistant to meropenem, imipe-
nem, aztreonam, sulbactam-ampicillin and aminoglyco-
sides. Antibiotic therapy with piperacillin-tazobactam
was given and continued for 14 days. Our patient contin-
ued to do well up to the time of surgery for the repair of
the congenital heart disease two months later.
Discussion
The genus Chryseobacterium belongs to the family Flavo-
bacteriaceae. Six species of Chryseobacterium are more
commonly isolated from clinical specimens: C. meningosep-
ticum, C. odoratum, C. multivorum, C. breve and group IIb
Chryseobacterium spp., which includes C. indologenes and
C. gleum. Chryseobacterium spp. are Gram-negative, aero-
bic, non-fermentative, oxidase-positive and catalase-positive
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pigment [1]. They are widely distributed in nature and
found primarily in soil and water. They are not normally
present in the human microflora [1,2]. They can survive in
chlorinated waters, and in the hospital environment they
exist in water systems and wet surfaces and serve as poten-
tial reservoirs of infection. Colonization of patients via con-
taminated medical devices such as respirators, endotracheal
and tracheostomy tubes, humidifiers, incubators for new-
borns and syringes has been documented previously [2,3].
Contaminated surgically implanted devices such as intra-
vascular catheters and prosthetic valves have also been
reported [4]. Chryseobacterium infections in humans are
usually acquired nosocomially and are frequently associated
with the presence of invasive equipment (intra-vascular
catheters, endotracheal tubes, prosthetic device) in immu-
nocompromised patients or patients who have received
long-term broad-spectrum antibiotics [4,5]. C. meningosep-
ticum is the most pathogenic member of the genus; it is an
agent of neonatal meningitis with mortality rates of up to
57% and is involved to a lesser extent in cases of pneumo-
nia and bacterial sepsis in neonates and adults [6] C. indolo-
genes is an uncommon human pathogen. The clinical
significance of C. indologenes has not been fully established
yet because this bacterium has not been frequently recov-
ered from clinical specimens. Reported infections include
bacteriemia, ventilator-associated pneumonia, indwelling
device-associated infection, pyonephritis, biliary tract infec-
tion, peritonitis, lumboperitoneal shunt infection, ocular
infections, and surgical and burn wound infections, and
infection has been associated with a high mortality rate
[4,5,7-13].
In the literature we have found six cases published of
infections for C. indologenes in children; all of the
patients were older than three months of age [9-13].
Hsueh et al. [9,10] reported three pediatric cases of
C. indologenes bacteremia. The first two patients were a
one-year-old girl and a five-year-old girl, both receiving
chemotherapy for a neoplastic disease and both with
indwelling central venous catheters. The third patient
was a one-year-old boy with a burn injury who was
under mechanical ventilation. The one-year-old boy
with burns developed an adult respiratory syndrome and
died despite antimicrobial treatment; the other two
patients recovered after three days of treatment. Cascio
et al. [11] reported on a two-year-old boy with type 1
diabetes mellitus who developed bacteremia. The only
medical device present was a peripheral catheter. The
patient received antimicrobial treatment with ceftriaxone
and recovered after two days.
In 2007, Bayraktar et al. [12] reported on a blood-
stream infection in a five-month-old baby. Molecular
typing with arbitrarily primed polymerase chain reaction
demonstrated the cross-contamination of commercial
distillate water. The baby was infected by this water
as a result of medical assistance received during
hospitalization.
Al-Tatari et al. [13] reported on a lumboperitoneal
shunt infection in a 13-year-old boy with congenital
hydrocephalus successfully treated with trimethoprim-
sulfamethoxazole and rifampim.
To the best of our knowledge, our patient’s case is the
first reported example of infection caused by C. indolo-
genes in a newborn. Appropriate choice of effective antimi-
crobial agents for treatment of infection by C. indologenes
is difficult because of the unpredictability and breadth of
antimicrobial resistance of these organisms, which often
involves resistance to many of the antibiotics chosen
empirically for serious Gram-negative infections.
C. indologenes is often resistant to extended-spectrum
penicillins, first-generation and second-generation
cephalosporins, ceftriaxone, aztreonam, ticarcillin-clavu-
lanate, chloramphenicol, erythromycin, aminoglycosides,
imipenem and meropenem for production of a class B
carbapenem-hydrolyzing enzyme.
C. indologenes is usually susceptible to piperacillin
alone or combined with tazobactam, ceftazidime, cefe-
pime, fluoroquinolones, rifampin and cotrimoxazole, but
the in vitro susceptibility to these antibiotics should be
systematically tested.
Antimicrobial susceptibility data on Chryseobacterium
spp. remain very limited because this pathogen has rarely
been isolated from clinical specimens. The results of the
evaluation of a worldwide collection indicate that the
newer quinolones (garenoxacin, gatifloxacin, and levoflox-
acin) may represent the most appropriate antimicrobial
agents to treat infections caused by this pathogen. Gare-
noxacin was the most active quinolone (minimum inhibi-
tory concentration required to inhibit the growth of 50%
of organisms (MIC50): 0.12 μg/mL); gatifloxacin (MIC50:
0.25 μg/mL) and levofloxacin (MIC50: 0.5 μg/mL) also
inhibited 98.0% of the isolates, and the rate of susceptibil-
ity to ciprofloxacin (MIC50: 0.5 μg/mL) was significantly
lower. Trimethoprim-sulfamethoxazole showed reasonable
activity. Among the b-lactams, the most active agents
overall were piperacillin-tazobactam (MIC50: 4 μg/mL;
80.0% susceptibility), piperacillin (MIC50: 8 μg/mL; 74.0%
susceptibility), and cefepime (MIC50: 8 μg/mL; 62.0% sus-
ceptibility). The carbapenems (6% to 12% susceptible) and
the aminoglycosides (8% to 14% susceptible) exhibited
poor activity against these pathogens [14].
Conclusion
C. indologenes should be considered as a potential patho-
gen in newborns in the presence of invasive equipment or
on treatment with long-term broad-spectrum antibiotics.
Appropriate choice of effective antimicrobial agents for
treatment is difficult because of the unpredictability and
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which often involves resistance to many of the antibiotics
chosen empirically for serious Gram-negative infections.
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